Redcare Pharmacy stock: Barclays raises target to EUR 86

Published on 11/13/2026 at 18:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock faces a higher Barclays target while its Overweight rating remains unchanged. Prescription growth and the path to stronger margins remain central for investors.

Key points for investors

Barclays retained its Overweight rating while revising its Redcare Pharmacy target upward.
Redcare's October 29 quarterly release showed strong prescription growth and improved adjusted profitability.
The January 11, 2027 trading update is the next scheduled company publication.

Redcare Pharmacy, NL0012044747, Illustration mit AI erstellt.

Barclays raised its price target for Redcare Pharmacy from EUR 85 to EUR 86 on Friday, November 13, 2026, while maintaining an Overweight rating. The update was reported by Finanzen.at, which identified Barclays analyst Andrew Ross as the author of the revised estimates.

Analyst target moves higher

The original Barclays study was released on November 12 and first distributed on November 13. The bank adjusted its estimates for Redcare Pharmacy and DocMorris after the companies' recent reporting and capital-markets updates. The unchanged rating signals that Barclays kept its broader assessment intact while lifting the target.

Prescription growth supports scale

In its October 29 third-quarter release, Redcare Pharmacy reported group revenue of EUR 847 million, up 18 percent year over year. Prescription revenue increased 31 percent to EUR 358 million, with Germany up 56 percent to EUR 197 million.

Adjusted EBITDA rose 68 percent to EUR 28.7 million, lifting the margin to 3.4 percent from 2.4 percent a year earlier. The active customer base reached 15.2 million, while management confirmed its upgraded 2026 targets for revenue growth, German prescription revenue and adjusted EBITDA margin.

Trading context and next dates

Redcare Pharmacy stock traded at EUR 68.53 on Lang & Schwarz at 18:07 CET on Friday, November 13, 2026. Investors will next look to the company's January 11, 2027 trading update for evidence on prescription momentum, customer growth and operating leverage.

European equities remain the wider market backdrop; see Current market reports.

More company-specific coverage is available in more news and analyses on Redcare Pharmacy stock.